30.90

0.02% 0.010

Zai Lab Limited Adr (ZLAB)

Overview News Price History Option Chain Financials Why ZLAB Down? Discussions Forecast

Zai Lab Limited Adr stock is traded at $30.90, with a volume of 263.68K. It is up +0.02% in the last 24 hours and up +17.20% over the past month. Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Previous Close:

$30.89

Open:

$31.61

24h Volume:

263.68K

Relative Volume:

0.36

Market Cap:

$3.08B

Revenue:

$266.72M

Net Income/Loss:

$-334.62M

P/E Ratio:

-7.5366

EPS:

-4.1

Net Cash Flow:

$-206.67M

1W Performance:

-1.70%

1M Performance:

+17.20%

6M Performance:

+90.12%

1Y Performance:

+20.12%

1-Day Range:

$30.62

$31.61

1-Week Range:

$30.01

$31.66

52-Week Range:

$13.48

$36.60

Zai Lab Limited Adr Stock (ZLAB) Company Profile

Name

Zai Lab Limited Adr

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

862161632588

Address

4560 JINKE ROAD, SHANGHAI

Employee

2,175

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

ZLAB's Discussions on Twitter

Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Morgan Stanley	Overweight
Aug-10-23	Initiated	Cantor Fitzgerald	Overweight
Jan-21-22	Initiated	Macquarie	Outperform
Oct-12-21	Initiated	Bernstein	Mkt Perform
Apr-28-20	Initiated	Goldman	Buy
Apr-15-20	Initiated	Guggenheim	Buy
Jul-12-19	Initiated	BofA/Merrill	Buy
Jul-05-19	Initiated	Macquarie	Outperform
Jan-29-19	Initiated	Credit Suisse	Outperform
Nov-21-18	Initiated	Jefferies	Buy
Jun-21-18	Resumed	Leerink Partners	Outperform
Feb-14-18	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Initiated	JP Morgan	Neutral
Oct-16-17	Initiated	Leerink Partners	Outperform

View All

Zai Lab Limited Adr Stock (ZLAB) Latest News

03:45 AM

Zai Lab Limited (NASDAQ:ZLAB) Holdings Trimmed by Mirae Asset Global Investments Co. Ltd. - MarketBeat

03:45 AM

Nov 04, 2024

JP Morgan analysts reiterates an Overweight rating for Roku Inc (ROKU) - Knox Daily

Nov 04, 2024

Oct 29, 2024

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China - Business Wire

Oct 29, 2024

Oct 27, 2024

Zai Lab (NASDAQ:ZLAB) Stock Price Down 3.7% – Here’s What Happened - Defense World

Oct 27, 2024

Oct 26, 2024

Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last? - MSN

Oct 26, 2024

Oct 25, 2024

Biopharma operator Zai Lab surges to 16-month high on lung cancer drug trial results - Mugglehead

Oct 25, 2024

Trial highlights potential next-gen biologic for lung cancer - Marketscreener.com

Oct 25, 2024

Zai Lab (NASDAQ:ZLAB) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat

Oct 25, 2024

Zai Lab (NASDAQ:ZLAB) Shares Down 3.7%What's Next? - MarketBeat

Oct 25, 2024

Hennion & Walsh Asset Management Inc. Boosts Stake in Zai Lab Limited (NASDAQ:ZLAB) - MarketBeat

Oct 25, 2024

Zai Lab stock soars to 52-week high, touches $32.5 - Investing.com India

Oct 25, 2024

Oct 24, 2024

Citi raises Zai Lab target on promising trial results - Investing.com

Oct 24, 2024

This Biotech Leader Just Hit A 16-Month High On An 'Impressive' Test - Investor's Business Daily

Oct 24, 2024

Zai Lab (NASDAQ:ZLAB) Hits New 12-Month HighHere's What Happened - MarketBeat

Oct 24, 2024

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer - BioSpace

Oct 24, 2024

Oct 21, 2024

Zai Lab Announces Participation in November and December Investor Conferences - BioSpace

Oct 21, 2024

JPMorgan Chase & Co. Raises Zai Lab (NASDAQ:ZLAB) Price Target to $44.00 - MarketBeat

Oct 21, 2024

Oct 20, 2024

Zai Lab (NASDAQ:ZLAB) Shares Up 6.5% – Still a Buy? - Defense World

Oct 20, 2024

Oct 18, 2024

Zai Lab (NASDAQ:ZLAB) Stock Price Up 6.5%Here's What Happened - MarketBeat

Oct 18, 2024

Oct 17, 2024

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 - Business Wire

Oct 17, 2024

Oct 16, 2024

Zai Lab (NASDAQ:ZLAB) Shares Gap UpShould You Buy? - MarketBeat

Oct 16, 2024

Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024 - BioSpace

Oct 16, 2024

Oct 15, 2024

Dimensional Fund Advisors LP Acquires New Shares in Zai Lab Limited (NASDAQ:ZLAB) - Defense World

Oct 15, 2024

An Analysis of Zai Lab Limited ADR (ZLAB)’s Potential Price Growth - Knox Daily

Oct 15, 2024

Recent Insider Activity Could Benefit Booz Allen Hamilton Holding Corp (BAH) - Knox Daily

Oct 15, 2024

Examining the Potential Price Growth of Phillips 66 (PSX) - Knox Daily

Oct 15, 2024

Verona Pharma Plc ADR [VRNA] Insider Activity: An Update for Investors - Knox Daily

Oct 15, 2024

Analyzing First Solar Inc (FSLR) After Recent Trading Activity - Knox Daily

Oct 15, 2024

Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily

Oct 15, 2024

Ratios in Focus: Analyzing Zai Lab Limited ADR (ZLAB)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 15, 2024